RRML - Hemoglobin clinical decision limits: Chasing the numbers
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- February 2026 -
 
Hematologic predictors of in-h... 5
Establishment of intra- and in... 5
Functional insights into a rar... 4
Serum Beta-Klotho as a damage-... 4
Comparative analysis of the im... 4
New immunodiagnostic tests for... 3
The evaluation of a diagnostic... 3
Assessment of preoperative and... 3
Effects of nitroglycerin combi... 3
Malignant transformation of th... 2

Log in

Concept, Design & Programming
Dr. Adrian Man
   
 
Nr. 34(1)/2026 DOI:10.2478/rrlm-2026-0004
XML
TXT

Review

Hemoglobin clinical decision limits: Chasing the numbers

Oana Oprea, Elena Cristina Preda

Correspondence should be addressed to: Elena Cristina Preda

Abstract:

Background: The interpretation of hemoglobin (Hb) values in clinical practice involves both absolute thresholds and relative changes, yet alignment between clinical decision limits (CDLs) and laboratory quality control (QC) thresholds is unclear. This study aimed to compare published CDLs for Hb used in diagnosis and treatment with those applied in laboratory internal QC processes. Methods: A literature search was conducted in PubMed (2018–2023) targeting adult populations. Eligible studies reported specific Hb thresholds or clinically relevant changes; case reports, case-control studies, and papers lacking these data were excluded. Results: Out of 507 initial articles, 131 met eligibility criteria. Among these, 121 referenced significant changes in Hb values, with a mean change of 1.08 g/dL (range: 0.50–3.50 g/dL). The most frequently cited clinically meaningful change was 2.00 g/dL. Conversely, changes under 0.40 g/dL (mean 0.39 g/dL) were generally considered clinically insignificant. Transfusion thresholds were consistently reported at 7.00–8.00 g/dL. Values of 10.00, 11.50, 12.00, and 13.00 g/dL were cited across studies involving CKD hemodialysed and non-hemodialysed patients, anemia, or patient stratification. Conclusions: There is substantial heterogeneity in reported Hb CDLs across clinical contexts. Current QC thresholds may overlook variations important to clinicians. Harmonizing QC strategies with clinical practice could enhance measurement reliability and patient care.

Keywords: biological variation, clinical decision-making, hemoglobin, quality control, laboratory

Received: 26.10.2025
Accepted: 9.12.2025
Published: 13.1.2026

 
  PDF Download full text PDF
(518 KB)